Susanne Fiedler - Organon Executive Officer
| OGN Stock | USD 15.69 0.57 3.77% |
Executive
Susanne Fiedler is Executive Officer of Organon Co
| Age | 56 |
| Address | 30 Hudson Street, Jersey City, NJ, United States, 07302 |
| Phone | 551 430 6900 |
| Web | https://www.organon.com |
Susanne Fiedler Latest Insider Activity
Tracking and analyzing the buying and selling activities of Susanne Fiedler against Organon stock is an integral part of due diligence when investing in Organon. Susanne Fiedler insider activity provides valuable insight into whether Organon is net buyers or sellers over its current business cycle. Note, Organon insiders must abide by specific rules, including filing SEC forms every time they buy or sell Organon'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Susanne Fiedler over three months ago Disposition of 1145 shares by Susanne Fiedler of Organon at 20.35 subject to Rule 16b-3 |
Organon Management Efficiency
The company has Return on Asset of 0.0791 % which means that on every $100 spent on assets, it made $0.0791 of profit. This is way below average. Organon's management efficiency ratios could be used to measure how well Organon manages its routine affairs as well as how well it operates its assets and liabilities. As of the 11th of December 2024, Return On Capital Employed is likely to grow to 0.29, while Return On Tangible Assets are likely to drop 0.14. At this time, Organon's Other Current Assets are very stable compared to the past year. As of the 11th of December 2024, Non Current Assets Total is likely to grow to about 7.7 B, while Total Assets are likely to drop about 11.9 B.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Deborah JD | Gilead Sciences | 59 | |
| William Winters | Novartis AG ADR | 60 | |
| Tracie Haas | AbbVie Inc | N/A | |
| Eric Dozier | Eli Lilly and | 56 | |
| Roopal MD | AbbVie Inc | 52 | |
| Andreas Panayiotou | Pfizer Inc | N/A | |
| Charles Sawyers | Novartis AG ADR | 62 | |
| WulffErik Borcke | AbbVie Inc | N/A | |
| Timothy Schmid | Johnson Johnson | 54 | |
| Natalie Bickford | Sanofi ADR | 54 | |
| Jim Greffet | Eli Lilly and | N/A | |
| Jerry Murry | Amgen Inc | N/A | |
| Johannes Oosthuizen | Merck Company | 56 | |
| Duane Arsdale | Johnson Johnson | N/A | |
| Elizabeth Shea | AbbVie Inc | N/A | |
| Roy Papatheodorou | Sanofi ADR | 46 | |
| Alan Russell | Amgen Inc | N/A | |
| Bertrand Bodson | Novartis AG ADR | 44 | |
| Vasant MD | Novartis AG ADR | 48 | |
| Annette Doherty | Pfizer Inc | N/A | |
| Giovanni MD | Bristol Myers Squibb | 59 | |
Management Performance
| Return On Asset | 0.0791 |
Organon Leadership Team
Elected by the shareholders, the Organon's board of directors comprises two types of representatives: Organon inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Organon. The board's role is to monitor Organon's management team and ensure that shareholders' interests are well served. Organon's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Organon's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthew Walsh, Executive CFO | ||
| Susan ONeal, Chief Officer | ||
| Matthew CFA, Executive CFO | ||
| Rebecca Edwards, Chief Officer | ||
| Rachel Stahler, Executive Officer | ||
| Susanne Fiedler, Executive Officer | ||
| Daniel Karp, Executive Development | ||
| Aaron Falcione, Executive Officer | ||
| Geralyn Ritter, Sustainability Affairs | ||
| Kevin Ali, CEO Director | ||
| Meghan Rivera, US Director | ||
| Jennifer Halchak, Vice Relations | ||
| Joseph Morrissey, Executive Supply | ||
| Kirke Weaver, General VP | ||
| Vittorio Nisita, Executive Services | ||
| MD JD, Ex RD |
Organon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Organon a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | 0.0791 | ||||
| Profit Margin | 0.20 % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | 11.88 B | ||||
| Shares Outstanding | 257.54 M | ||||
| Shares Owned By Insiders | 0.18 % | ||||
| Shares Owned By Institutions | 81.71 % | ||||
| Number Of Shares Shorted | 14.72 M | ||||
| Price To Earning | 4.20 X | ||||
| Price To Book | 7.90 X |
Pair Trading with Organon
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Organon position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Organon will appreciate offsetting losses from the drop in the long position's value.Moving together with Organon Stock
Moving against Organon Stock
| 0.92 | BMY | Bristol Myers Squibb | PairCorr |
| 0.83 | GILD | Gilead Sciences | PairCorr |
| 0.78 | CAH | Cardinal Health | PairCorr |
| 0.74 | ESPR | Esperion Therapeutics | PairCorr |
| 0.64 | XAIR | Beyond Air | PairCorr |
The ability to find closely correlated positions to Organon could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Organon when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Organon - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Organon Co to buy it.
The correlation of Organon is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Organon moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Organon moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Organon can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organon Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organon. If investors know Organon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organon listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.081 | Dividend Share 1.12 | Earnings Share 5.05 | Revenue Per Share 24.984 | Quarterly Revenue Growth 0.041 |
The market value of Organon is measured differently than its book value, which is the value of Organon that is recorded on the company's balance sheet. Investors also form their own opinion of Organon's value that differs from its market value or its book value, called intrinsic value, which is Organon's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organon's market value can be influenced by many factors that don't directly affect Organon's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Organon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organon's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.